UK markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.83000.0000 (0.00%)
At close: 04:00PM EST
0.8470 +0.02 (+2.05%)
After hours: 07:43PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.13
52-week change 3-36.64%
S&P500 52-week change 3-7.75%
52-week high 31.6200
52-week low 30.5000
50-day moving average 30.7110
200-day moving average 30.8968

Share statistics

Avg vol (3-month) 3565.92k
Avg vol (10-day) 3444.1k
Shares outstanding 5126.62M
Implied shares outstanding 6N/A
Float 8118.83M
% held by insiders 10.04%
% held by institutions 121.65%
Shares short (12 Jan 2023) 49.08M
Short ratio (12 Jan 2023) 414.48
Short % of float (12 Jan 2023) 47.17%
Short % of shares outstanding (12 Jan 2023) 47.17%
Shares short (prior month 14 Dec 2022) 49.59M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 319 Apr 2018
Ex-dividend date 4N/A
Last split factor 21:12
Last split date 319 Apr 2018

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-11.30%
Return on equity (ttm)-18.33%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -24.37M
Net income avi to common (ttm)-24.3M
Diluted EPS (ttm)-0.1740
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)117.37M
Total cash per share (mrq)0.93
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)43.03
Book value per share (mrq)0.97

Cash flow statement

Operating cash flow (ttm)-19.9M
Levered free cash flow (ttm)-10.28M